PATENT CLAIM ANALYSIS

Application Number: 16105522
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "04400A"]

Abstract:
The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

Claim (Index 12):
The composition of  claim 9 , wherein the composition comprises a second RNAi agent targeted to Beta-ENaC.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 96.0
- Lexical Diversity: 1.26829
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15661132', '15166576', '14723555', '13355903', '13355879']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8230878842494369
- 35 USC 102 Novelty (BERT): 0.6063905867169403
- Combined Prediction Score: 0.8014181544961873
- Mean Citation Score: 502.48829400000005
- Max Citation Score: 507.3577
- Similarity Product: 504.2658124089122

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test